Skip to main content
. 2016 Aug 26;9:77. doi: 10.3389/fnmol.2016.00077

Figure 6.

Figure 6

Intracellular signaling pathways involved in GSK1016790A-induced inhibition of IGABA. (A) GSK1016790A-induced inhibition of IGABA was markedly attenuated by either the AMPK antagonist Compound C or the PI3K agonist 740 Y-P but was not affected by the PI3K antagonist LY294002. Unpaired t-test, ∧∧P < 0.01 vs. GSK1016790A. (B) In the presence of the PKC antagonist D-sphingosine or BIM, the GSK1016790A-induced inhibition of IGABA was significantly reversed. Unpaired t-test, ∧∧P < 0.01 vs. GSK1016790A. (C,D) Pre-application of the PKA antagonists PKI or H-89 (C) or the CaMKII antagonists KN62 or KN93 (D) did not affect the GSK1016790A-induced inhibition of IGABA.